Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2020 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly Other Non Operating Income came in at -$55000.0 in Q1 2026, down 131.79% year-on-year from $173000.0 in Q1 2025, and down 10.0% quarter-over-quarter from -$50000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$55000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 131.79% year-over-year to -$55000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 140.48% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 155.87% from the prior year.
- Other Non Operating Income declined to -$55000.0 in Q1 2026 per GLUE's latest filing, from -$50000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.4 million in Q2 2025 and bottomed at -$3.1 million in Q4 2024.
- The 5-year median for Other Non Operating Income is -$50000.0 (2025), against an average of -$126294.1.
- Across the five-year window, Other Non Operating Income plunged 666.67% in 2024 and jumped 2722.64% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at -$283000.0 in 2022, then tumbled by 175.27% to -$779000.0 in 2023, then tumbled by 294.09% to -$3.1 million in 2024, then jumped by 98.37% to -$50000.0 in 2025, then fell by 10.0% to -$55000.0 in 2026.
- Per Business Quant, the three latest GLUE Other Non Operating Income figures stand at -$55000.0 (Q1 2026), -$50000.0 (Q4 2025), and -$29000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55,000.00 |
| Dec 31, 2025 | -50,000.00 |
| Sep 30, 2025 | -29,000.00 |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 173,000.00 |
| Dec 31, 2024 | -3.07 Mn |
| Sep 30, 2024 | -153,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | 620,000.00 |
| Dec 31, 2023 | -779,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | -93,000.00 |
| Mar 31, 2023 | -85,000.00 |
| Dec 31, 2022 | -283,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 96,000.00 |
| Dec 31, 2021 | -66,000.00 |
| Sep 30, 2021 | 18,000.00 |
| Jun 30, 2021 | -296,000.00 |